{"id":"phentolamine-mesylate-nv-101","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypotension"},{"rate":"5-10%","effect":"Tachycardia"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1200873","moleculeType":"Small molecule","molecularWeight":"377.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking alpha-adrenergic receptors, phentolamine mesylate causes blood vessels to dilate, which can help to reduce blood pressure and alleviate symptoms of pheochromocytoma. This mechanism of action is specific to the treatment of hypertension and pheochromocytoma.","oneSentence":"Phentolamine mesylate is an alpha-adrenergic receptor antagonist that works by blocking the action of norepinephrine, a neurotransmitter that can cause blood vessels to constrict.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:52.298Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Pheochromocytoma"}]},"trialDetails":[{"nctId":"NCT00309322","phase":"PHASE2","title":"Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures","status":"COMPLETED","sponsor":"Novalar Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Anesthesia, Dental","enrollment":150},{"nctId":"NCT00309361","phase":"PHASE3","title":"Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures","status":"COMPLETED","sponsor":"Novalar Pharmaceuticals, Inc.","startDate":"2006-02","conditions":"Anesthesia, Dental","enrollment":240},{"nctId":"NCT00309335","phase":"PHASE3","title":"Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures","status":"COMPLETED","sponsor":"Novalar Pharmaceuticals, Inc.","startDate":"2006-02","conditions":"Anesthesia, Dental","enrollment":240},{"nctId":"NCT00154167","phase":"PHASE2","title":"Safety and Efficacy Study of NV-101 in Dental Patients","status":"COMPLETED","sponsor":"Novalar Pharmaceuticals, Inc.","startDate":"2003-02","conditions":"Soft Tissue Anesthesia (Numbness)","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Phentolamine Mesylate (NV-101)","genericName":"Phentolamine Mesylate (NV-101)","companyName":"Novalar Pharmaceuticals, Inc.","companyId":"novalar-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Phentolamine mesylate is an alpha-adrenergic receptor antagonist that works by blocking the action of norepinephrine, a neurotransmitter that can cause blood vessels to constrict. Used for Hypertension, Pheochromocytoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}